<DOC>
	<DOCNO>NCT00476827</DOCNO>
	<brief_summary>Our hypothesis study design , bevacizumab add one six single agent chemotherapy prove activity metastatic breast cancer , result regression stabilization disease safe tolerable manner .</brief_summary>
	<brief_title>A Phase II Safety Tolerability Study Bevacizumab When Added Single-agent Chemotherapy Treat Patient With Breast Cancer Metastatic Brain</brief_title>
	<detailed_description>There unmet clinical need effective therapy breast cancer metastasize brain . In scenario , median survival around 12 month use currently available therapeutic intervention . The majority chemotherapy-based clinical trial consider presence central nervous system metastasis exclusion criterion due risk toxicity , inability chemotherapeutic agent cross blood brain barrier , limited overall survival within patient population . The preclinical data regard safety activity bevacizumab vascular endothelial growth factor ( VEGF ) -expressing tumor provide good rationale study patient breast cancer metastasis brain . Yano , et al . illustrated tumor cell expression VEGF messenger ribonucleic acid protein directly correlate angiogenesis growth brain metastasis nude mouse model . Transfecting experimental cell line know produce visceral metastasis anti-sense VEGF-gene significantly reduce incidence brain metastasis . Kim , et al . illustrated murine model specific brain metastasis originate breast cancer show elevated expression angiogenic permeability-inducing factor VEGF-A . The growth brain metastasis model attenuate addition VEGF-tyrosine kinase inhibitor via induction apoptosis decrease angiogenesis . VEGF also implicate development brain edema , significant source morbidity mortality associate brain metastasis . Enhanced level VEGF receptor report murine model induction cortical ischemia . Finally , antagonism VEGF demonstrate reduce immediate delay volume infarct . The optimal dose bevacizumab extensively study phase I trials alone combination chemotherapy . The safe effective dose establish 10 mg/kg q 14 day 15 mg/kg Q 21 day . In addition irinotecan paclitaxel , previously use phase II/III setting combination capecitabine , vinorelbine , gemcitabine , docetaxel . Phase III study show overall survival advantage bevacizumab add irinotecan/Fluorouracil ( 5FU ) -based regimen metastatic colorectal cancer , add weekly paclitaxel metastatic breast cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Female , 18+ , evaluable metastatic breast cancer stable brain metastasis Must receive definitive radiotherapy No evidence , history , central nervous system hemorrhage Adequate organ hematological function Active infection , nonhealing wound , history bleed diathesis coagulopathy Uncontrolled hypertension , congestive heart failure , peripheral vascular disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Brain</keyword>
	<keyword>Anti-angiogenesis</keyword>
</DOC>